Merit Medical Systems (NASDAQ:MMSI) Releases FY 2026 Earnings Guidance

02 May 2026, 12:10 by Amy Steele · The Cerbat Gem

Merit Medical Systems (NASDAQ:MMSI – Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 4.010-4.150 for the period, compared to the consensus estimate of 3.930. The company issued revenue guidance of $1.6 billion-$1.6 billion, compared to the consensus revenue estimate of $1.6 billion.

Merit Medical Systems Stock Performance

Merit Medical Systems stock traded down $6.17 during midday trading on Friday, hitting $62.01. 2,526,188 shares of the company’s stock were exchanged, compared to its average volume of 579,377. Merit Medical Systems has a 12-month low of $61.31 and a 12-month high of $100.19. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.95 and a current ratio of 4.34. The stock has a market cap of $3.70 billion, a price-to-earnings ratio of 29.25, a price-to-earnings-growth ratio of 1.93 and a beta of 0.64. The firm’s 50 day simple moving average is $70.68 and its 200 day simple moving average is $79.78.

Merit Medical Systems (NASDAQ:MMSI – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The medical instruments supplier reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.10. Merit Medical Systems had a net margin of 9.03% and a return on equity of 13.74%. The company had revenue of $381.88 million for the quarter, compared to the consensus estimate of $377.59 million. During the same period last year, the firm posted $0.86 EPS. Merit Medical Systems’s revenue for the quarter was up 7.4% on a year-over-year basis. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. Equities research analysts predict that Merit Medical Systems will post 3.61 EPS for the current year.

Analysts Set New Price Targets

MMSI has been the topic of several research reports. Wells Fargo & Company lowered their price objective on shares of Merit Medical Systems from $78.00 to $74.00 and set an “equal weight” rating on the stock in a research report on Friday. Citigroup reissued an “outperform” rating on shares of Merit Medical Systems in a research report on Monday, April 20th. Robert W. Baird set a $83.00 price objective on shares of Merit Medical Systems in a research report on Friday. Canaccord Genuity Group lowered their price objective on shares of Merit Medical Systems from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Merit Medical Systems in a research report on Friday, March 27th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, Merit Medical Systems presently has an average rating of “Moderate Buy” and a consensus target price of $92.80.

Read Our Latest Research Report on MMSI

Key Headlines Impacting Merit Medical Systems

Here are the key news stories impacting Merit Medical Systems this week:

Positive Sentiment: Q1 results beat and management raised guidance — Merit reported Q1 non‑GAAP EPS of $0.94 (vs. $0.84 est.) and revenue of ~$382M (beat). The company lifted FY2026 EPS guidance to $4.01–$4.15 and reiterated revenue targets, pointing to steady segment/geographic gains and improved margins and free cash flow. Press Release
Positive Sentiment: Operational highlights support durable cash generation — Management reported GAAP operating margin ~11.6%, non‑GAAP operating margin ~19.7%, and free cash flow up ~26%. These metrics support the company’s cash‑flow story and capital deployment (recent acquisition activity). Details
Positive Sentiment: Acquisition expands product set — Merit closed the View Point Medical acquisition (OneMark detection/tissue marker products) for $140M (cash portion $90M), and divested the DualCap line for $28M; these moves can bolster higher‑margin therapeutic offerings. Transaction Details
Neutral Sentiment: Earnings call / transcripts available — Call transcripts and highlights confirm beat and management commentary on organic growth, mix, and margin drivers; useful for investors who want management color. Earnings Call Transcript
Negative Sentiment: Analysts trimmed price targets — Several firms cut PTs today (JPMorgan: $95→$77, Wells Fargo: $78→$74, Needham: $101→$90). Although ratings were maintained (overweight/equal weight/buy), the cuts reflect multiple‑compression or sector re‑rating concerns and likely contributed to selling pressure. Analyst Notes (Benzinga)
Negative Sentiment: Market reaction driven by valuation vs. growth — Despite beats, some analysts flagged growth deceleration and applied lower sector multiples; with the stock already well off its 52‑week high, target trims can trigger headline-driven outflows. Analyst Commentary

Institutional Trading of Merit Medical Systems

Hedge funds and other institutional investors have recently made changes to their positions in the company. Los Angeles Capital Management LLC purchased a new stake in shares of Merit Medical Systems in the fourth quarter valued at about $25,000. Danske Bank A S purchased a new stake in shares of Merit Medical Systems in the third quarter valued at about $42,000. Quarry LP boosted its holdings in shares of Merit Medical Systems by 185.9% in the third quarter. Quarry LP now owns 526 shares of the medical instruments supplier’s stock valued at $44,000 after acquiring an additional 342 shares in the last quarter. Global Retirement Partners LLC boosted its holdings in shares of Merit Medical Systems by 973.6% in the fourth quarter. Global Retirement Partners LLC now owns 569 shares of the medical instruments supplier’s stock valued at $50,000 after acquiring an additional 516 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its holdings in shares of Merit Medical Systems by 745.9% in the second quarter. EverSource Wealth Advisors LLC now owns 922 shares of the medical instruments supplier’s stock valued at $86,000 after acquiring an additional 813 shares in the last quarter. Hedge funds and other institutional investors own 99.66% of the company’s stock.

About Merit Medical Systems

(Get Free Report)

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.